Merck stock

MRK · Xetra · EUR

€150.80Change from previous close: +0.80%Absolute change: +€1.20

Close · November 16, 2026

Price history

+30.28% over the period

1 year: from €115.75 (November 17, 2025) to €150.80 (November 16, 2026), +30.28%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026€150.80
October 30, 2026€151.30
September 30, 2026€138.10
August 31, 2026€139.00
July 31, 2026€143.15
June 30, 2026€146.85
May 29, 2026€130.85
April 30, 2026€110.05
March 31, 2026€107.60
February 27, 2026€128.30
January 30, 2026€125.55
December 30, 2025€122.60
November 28, 2025€116.00
November 17, 2025€115.75

At a glance

  • The company

    Science and technology company offering life science products and services, healthcare pharmaceuticals, and advanced materials for electronics and semiconductors

  • Latest results

    Quarter to September 30, 2026 · EPS €2.32 (estimate €2.09)

TickerLandia's take on Merck

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€100.70
52-wk high€156.25

−3.49% from the 52-week high

Analysts · 14 analysts

Average target€156.86+4.02% vs. price

Buy 6 · Hold 8 · Sell 0 · Buy

TickerLandia Fingerprint: Merck

Compared with similar companies: very low growth.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Merck is priced as in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Merck's P/E today is 25.1, in line with the median of its last 10 fiscal years (25.0; between 15.3 and 36.5 from 2016 to 2025). Merck's P/E (trailing 12 months): 33.8, +35% against the median of a group of 11 similar companies (25.0).

P/E compared with its history

Compared with 11 similar companies

Merck's metrics compared with similar companies
MetricMerckPosition in the groupBand
P/E (trailing 12 months)33.8High
Forward P/E16.4Middle
Operating margin17.0%Middle
ROE6.4%Low
Debt/equity0.38Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Merck. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€5.63B

Latest quarter · Q3 2026

Net income

€450M

Latest quarter · Q3 2026

Quarterly net margin

8.0%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
€65.04B
P/E
33.8
EPS
€4.42
Volume
283.64K
Daily trading
€43.48M
Dividend yield
1.46%
Last ex-dividend on April 27, 2026

How Merck is changing

All results
  • Revenue grew 3.8% a year on average over the last 5 years

  • Operating margin fell from 22.4% to 18.6%

  • Free cash flow equal to 88% of net income

Returns

Merck returns with dividends

€1,000 invested in Merck 5 years ago, on November 16, 2021, would be worth €755 today with dividends reinvested: −24.48% in total, −5.46% per year. On price alone it would be €699 (−30.06%).

PeriodMerckDAX€1,000 becomes
1 month+4.50%+5.90%€1,045
6 months+28.50%+11.69%€1,285
Year to date+23.00%+9.23%€1,230
1 year+32.91%+13.39%€1,329
3 years+2.41%+69.45%€1,024
5 years−24.48%+64.64%€755
10 years+83.74%+150.85%€1,837

Over the last 6 months it has done better than 50% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. DAX: with dividends. Calculate your investment

The chart in detail

Merck: technical analysis

Merck is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 34.3% below its all-time closing high (€229.40, December 28, 2021).

Trend
Upward
RSI (14 sessions)
60
Between 30 and 70
vs 200-session average
+15.35%

Support and resistance

Price areas where Merck has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price€150.80
  3. Support€148.72−1.38%2 touches, last on August 6, 2026
  4. Support€141.48−6.18%3 touches, last on October 22, 2026
  5. Support€132.00−12.47%3 touches, last on October 2, 2026

Volatility and risk

Over the last year it has moved roughly in line with the DAX.

Beta (1 year) vs DAX
0.81
Volatility (60 sessions, annualised)
21.8%
Largest fall in the last year
−21.68%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Merck: seasonality

Average monthly price change over 29 years

+1.2%Jan−1.7%Feb+1.2%Mar+1.8%Apr+1.9%May−0.6%Jun+0.7%Jul−0.1%Aug+0.3%Sep+1.8%Oct+3.3%Nov+0.7%Dec

Over the last 29 years, the strongest month for Merck has been November: +3.31% on average, positive in 20 years out of 28. The weakest has been February: −1.68% on average, positive in 11 years out of 28.

Show chart data
MonthAverageMedianPositive years
January+1.17%+2.57%18 of 28
February−1.68%−2.10%11 of 28
March+1.16%+2.93%15 of 28
April+1.79%+1.11%17 of 28
May+1.92%+0.36%15 of 28
June−0.63%+0.03%14 of 28
July+0.65%+0.60%18 of 29
August−0.13%+0.35%15 of 29
September+0.27%+0.35%15 of 29
October+1.78%−1.08%14 of 29
November+3.31%+2.83%20 of 28
December+0.75%+0.46%15 of 28

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Merck and its competitors

Revenue of EUR 21.1 billion comes from three segments that serve very different customers. Life Science supplies academic, research and diagnostic laboratories, biotech and pharmaceutical companies, and industrial clients with reagents, consumables, lab water instruments and flow cytometry kits, along with bioprocessing products such as chromatography resins and single-use systems, and contract development and manufacturing services. Healthcare develops and sells prescription drugs and biopharmaceuticals for oncology, rare diseases, neurology, immunology, fertility, cardiovascular and metabolic disorders.

Headquarters
Darmstadt, Germany
Employees
61,949
Founded
1668
Chief executive
Kai Beckmann
Merck and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
MerckMRK$71.89B17.0%33.8+28.50%
Galderma GroupGALD$53.24B19.1%66.0+22.82%
Sandoz GroupSDZ$43.66B9.3%72.3+30.60%
HaleonHLN$40.03B23.5%19.2+4.51%
Swedish Orphan BiovitrumSOBI$16.42B30.9%25.0+8.39%
IpsenIPN$15.16B27.4%26.9+0.60%

Same industry or related industries, similar size. Compare Merck with its competitors · Full profile